top of page
spyglass_IOL_eluting.jpg

Welcome to
SpyGlass Pharma™

At SpyGlass Pharma™, we're innovating at the intersection of Cataract Surgery and Glaucoma/Ocular Hypertension treatment.

Understanding Cataracts and Cataract Surgery

shutterstock_593311505.jpg

What is a Cataract?

A cataract is a common eye condition where the lens of your eye becomes cloudy, affecting your vision.

Cataract Surgery:
A Clearer View

Cataract Surgery involves replacing the cloudy lens with a clear artificial lens, known as an Intraocular Lens (IOL), to restore clear vision.

iol.jpg

Glaucoma and Ocular Hypertension

glaucoma.jpg

Glaucoma: More than Just Eye Pressure

Glaucoma is a group of eye conditions that damage the optic nerve, crucial for good vision, often due to high eye pressure.

Treating Glaucoma and Ocular Hypertension

Typical treatments include daily eye drops, laser treatments, or surgical options like drainage devices.

bottles.jpg

Introducing the SpyGlass Pharma Drug Delivery Platform

The SpyGlass Pharma™ Drug Delivery Platform is designed to provide years of proven medication to lower Intraocular Pressure (IOP) at the time a patient has cataract surgery

The SpyGlass Pharma™ Drug Delivery Platform has not been approved by the FDA

The SpyGlass Pharma™ Drug Delivery Platform consists of a single-piece, hydrophobic acrylic IOL and two drug eluting pads that slide over each haptic and securely attach at the haptic junction. With the drug pads securely attached, the IOL and pads are loaded into a standard IOL injector. The lens is advanced and injected through a sub 2.4 mm incision and implanted directly into the capsular bag. 

The drug pads remain outside the visual axis and continuously elute directly into the aqueous humor, which carries the active drug to targeted tissues. 

HOW IT WORKS

During cataract surgery, your doctor will implant a SpyGlass IOL that is uniquely designed to provide both good vision and allow for drug pads to be secured to the haptics of the IOL.  These drug pads have multiple years of IOP-lowering medication in them that will slowly elute a small amount of medication continuously every day.

IOL_pads_outline.jpg

SPYGLASS TECHNOLOGY: A STEP INTO THE FUTURE

SpyGlass Drug Delivery Platform is currently being studied in a US FDA clinical trial evaluating safety and efficacy of the SpyGlass platform with bimatoprost.

Bimatoprost is an IOP-lowering therapy that has been FDA approved for over 20 years and has been used by millions of patients around the world to treat their glaucoma or ocular hypertension.

The SpyGlass Drug Delivery Platform is limited by Federal (or United States) law to investigational use.

spyglass_pharma_pipeline.jpg

BEYOND CATARACT SURGERY: THE SPYGLASS PIPELINE

SpyGlass technology is also being developed to elute other ophthalmic medication for chronic Eye conditions.  

SpyGlass Pharma™ is additionally developing a Platform Extension that is designed to provide additional years of IOP lowering therapy after a patient has had cataract surgery.  

This platform extension is being developed to give patients additional options beyond the initial treatment implanted at the time of Cataract surgery, allowing patients to continue enjoying SpyGlass technology for many years to come. 

texture_bg.jpg

SpyGlass Pharma™ Strengthens Leadership to Further Advance its Intraocular Drug Delivery Platform

ALISO VIEJO, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today announced the appointments of Margot Goodkin, M.D., Ph.D., as Chief Medical Officer and Bilal Khan, MBA, to the SpyGlass Board of Directors. Dr. Goodkin and Mr. Khan each bring a wealth of experience to support the growth and continued development of the SpyGlass intraocular drug delivery platform. (View full press release)

bottom of page